TD Cowen Maintains Medtronic(MDT.US) With Buy Rating, Maintains Target Price $95
Medtronic's Growth Potential and Favorable Market Conditions Reinforce Buy Rating
BofA Securities Maintains Medtronic(MDT.US) With Buy Rating
Bank of America Securities Keeps Their Buy Rating on Medtronic (MDT)
Barclays Maintains Medtronic(MDT.US) With Buy Rating, Maintains Target Price $105
Barclays Remains a Buy on Medtronic (MDT)
Analysts Have Conflicting Sentiments on These Healthcare Companies: PTC Therapeutics (PTCT), Medtronic (MDT) and OptimizeRx (OPRX)
Wells Fargo Maintains Medtronic(MDT.US) With Buy Rating, Maintains Target Price $106
BofA Securities Maintains Medtronic(MDT.US) With Buy Rating, Maintains Target Price $100
BofA Securities Maintains Medtronic(MDT.US) With Buy Rating, Maintains Target Price $100
Medtronic Analyst Ratings
BofA Securities Maintains Medtronic(MDT.US) With Buy Rating, Maintains Target Price $100
Needham Maintains Medtronic(MDT.US) With Hold Rating
BofA Securities Maintains Medtronic(MDT.US) With Buy Rating, Maintains Target Price $100
Medtronic (MDT) Gets a Hold From Stifel Nicolaus
Baird Maintains Medtronic(MDT.US) With Hold Rating, Raises Target Price to $96
Truist Financial Maintains Medtronic(MDT.US) With Hold Rating, Raises Target Price to $93
Medtronic Analyst Ratings
Truist Raises Price Target on Medtronic to $93 From $90, Maintains Hold Rating
Morgan Stanley Maintains Medtronic(MDT.US) With Buy Rating, Maintains Target Price $98